Pharmacology of S21402 (RB105): A dual inhibitor of neutral endopeptidase and angiotensin converting enzyme

Cardiovascular Drug Reviews

Volumn 14, Issue 2, 1996, Pages 166-184

  Gonzalez, Walter ^a   Fournié Zaluski, Marie Claude ^b   Turcaud, Serge ^b   Reques, Bernard Pierre ^b   Michel, Jean Baptiste ^a  

^a INSERM   (France)

^b CNRS   (France)

Author keywords

ACE inhibitor; Atrial natriuretic peptide; Hypertension; Myocardial infarction; NEP inhibitor; RB105; SB21402

Indexed keywords

ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE; PRODRUG; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; DOSE RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NATRIURESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VASODILATATION;

EID: 0029841925     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1996.tb00225.x     Document Type: Article

References (78)

1. Abassi Z, Haramati A, Hoffman A, Burnett JC, Winaver J. Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure Am J Physiol 1990,259:R84-89.
2. Abassi ZA, Tate JE, Golomb E, Keiser HR. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992;20:89-95.
3. Arnal JF, Battle T, Rasetti C, et al. ACE in three tunicae of rat aorta: Expression in smooth muscle and effect of renovascular hypertension. Am J Physiol 1994;267:H1777-H1784.
4. Aviv R, Gurbanov K, Hoffman A, Blumberg S, Winaver J. Urinary neutral endopeptidase 24.11 activity: Modulation by chronic salt loading. Kidney Int 1995;47:855-860.
5. Bralet J, Marie C, Mossiat C, Lecomte JM, Gros C, Schartz JC. Effects of alatripril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. J Pharmacol Exp Ther 1994;270:8-14.
6. Burnett J, Kao P, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231.1145-1147.
7. Cachofeiro V, Nasjletti A. Increased vascular responsiveness to bradykinin in kidneys of spontaneously hypertensive rats. Hypertension 1991;18:683-688.
8. Caldwell RB, Seegal BC, Hsu K, Das M, Soffer R. Angiotensin-converting enzyme: Vascular endothelial localization. Science 1976;191:1050-1051.
9. Carbonell LF, Carretero OA, Stewart JM, Scicli AG. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988,11:239-243.
10. Carretero O, Miyazaki S, Scicli A. Role of kinins in acute antihypertensive effect of the converting enzyme inhibitor, captopril. Hypertension 1981;3:18-22.
11. Cody R, Laragh J, Kubo S, Covit B, Ryman S, Shaknovich A Atrial natriuretic factor in normal subjects and heart failure. J Clin Invest 1986;78:1362-1374.
12. Defendini R, Zimmerman EA, Weare JA, Alhenc-Gelas F, Erdos EG Angiotensin-converting enzyme in epithelial and neuroepithelial cells. Neuroendocrinology 1983,37.32-40.
13. Ding J, Thibault G, Gutkowska J, et al. Cardiac and plasma atrial natriuretic factor in experimental congestive heart failure. Endocrinology 1987;121:248-257
14. Dussaule JC, Stefanski A, Bea ML, Ronco P, Ardaillou R Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol 1992,32:45-52.
15. Erdos EG, Skidgel RA. The angiotensin I-converting enzyme Lab Invest 1987;56:345-348.
16. Falkenhahn M, Franke F, Bohle RM, et al Cellular distribution of angiotensin-converting enzyme after myocardial infarction Hypertension 1995;25:219-226.
17. Favrat B, Burnier M, Nussberger J, et al. Neutral endopeptidase versus angiotensin-converting enzyme inhibition in essential hypertension. J Hypertens 1995;1;3:797-804
18. Flynn GA, Beight DW, Mehdi S, et al. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combinated inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J Med Chem 1993,36:2420-2423.
19. Foumié-Zaluski MC, Coric P, Turcaude S, et al. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme. Rational design, bioavailability, and pharmacological responses in experimental hypertension. J Med Chem 1994;37:1070-1083
20. Fournié-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: A potential therapeutic approach in hypertension. Proc Natl Acad Sci 1994;91:4072-4076.
21. Fournie-Zaluski MC, Lucas E, Waksman G, Roques BP. Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin-converting enzyme. Molecular investigation by use of new thiol inhibitors. Eur J Biochem 1984;139:267-274.
22. French JF, Anderson BA, Downs TR, Dage RC. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J Cardiovasc Pharmacol 1995;26:107-113
23. Gafford JT, Skidgel RA, Erdos EG, Hersh LB. Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. Biochemistry 1983;22:3265-3271.
24. Gaillard CA, Koomans HA, Dorhout Mees EJ. Enalapril attenuates natriuresis of atrial natriuretic factor in humans. Hypertension 1988;11:160-165.
25. Gonzalez W, Beslot F, Laboulandine I, Fournié-Zaluski M-C, Roques BP, Michel J-B. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. J Pharmacol Exp Ther 1996 (in press).
26. Gonzalez W, Fournié-Zaluski MC, Pham I, Laboulandine I, Roques BP, Michel JB. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in hypertensive rats. J Pharmacol Exp Ther 1995,272:343-351.
27. Gros C, Noel N, Souque A, et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3 4.24.11): Rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci (USA) 1991;88:4210-4214.
28. Guyton AC. Renal function curve - A key to understanding the pathogenesis of hypertension. Hypertension 1987;10:1-6.
29. Hirsh A, Talsness C, Schunkert H, Paul M, Dzau V. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure Circ Res 1991,69.475-482.
30. Hooper NM Angiotensin-converting enzyme: Implications from molecular biology for its physiological functions. Int J Biochem 1991;23:641-647.
31. Johnson AR, Ashton J, Schultz WW, Erdos EG. Neutral endopeptidase in human lung tissue and cultured cells. Am Rev Respir Dis 1985;132:564-568.
32. 125I]atrial natriuretic factor by vascular smooth muscle cells. J Biol Chem 1989,264:11637-11642.
33. Lappe RW, Todt JA, Wendt RL. Effects of atrial natriuretic factor on the vasoconstrictor actions of the renin-angiotensin system in conscious rats. Circ Res 1987;61:134-140.
34. Lecomte JM, Baumer P, Lim C, et al. Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans. Eur J Pharmacol 1990;179:65-73.
35. Levy BI, Michel JB, Salzmann JL, et al. Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. Circ Res 1988;63:227-239.
36. Llorens-Cortes C, Huang H, Vicart P, Gasc JM, Paulin D, Corvol P Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins. J Biol Chem 1992;267:14012-14018.
37. Lorkowski G, Zijderhand-Bleekemolen JE, Erdos GE, Figura KV, Hasilik A. Neutral endopeptidase-24.11 (enkephalinase). Biochem J 1987;248:345-350.
38. Margulies KB, Perella MA, McKinley J, Burnett JC. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-1642.
39. Michel JB, Dussaule JC, Choudat L, et al. Effects of antihypertensive treatment in one-clip, two-kidney hypertension in rats. Kidney Int 1986;29:1011-1020.
40. Michel JB, Lattion AL, Salzman JL, et al. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ Res 1988,62:641-650
41. Michel JB, Mercadier JJ, Galen FX, et al. Urinary cyclic guanosine monophosphate as an indicator of experimental congestive heart failure in rats. Cardiovasc Res 1990;25:946-952.
42. Mizelle HL, Hall JE, Hildbrandt DA. Atrial natriuretic peptide and pressure natriuresis: Interactions with the renin-angiotensin system. Am J Physiol 1989;257:R1169-1174.
43. Mombouli JV, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 1995;35:679-705.
44. Olins GM, Krieter PA, Trapani AJ, Spear KL, Bovy PR. Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo. Mol Cell Endocrinol 1989;61:201-208.
45. Peyroux J, Beslot F, Claperon N, Fournié-Zaluski MC, Roques BP. Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide. Brit J Pharmacol 1995;116:3117-3124.
46. Pham I, El Amrani A-I, Fournié-Zaluski MC, Corvol P, Roques BP, Michel JB. Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats. J Cardiovasc Pharmacol 1992;20:847-857
47. Pham I, Gonzalez W, Doucet J. Fournié-Zaluski M-C, Roques BP, Michel J-B. Effects of angiotensinconverting enzyme and neutral endopeptidase inhibitors: Influence of bradykinin Eur J Pharmacol 1996; 296:267-276.
48. Pham I, Gonzalez W, El Amrani A-K, et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993;265:1339-1347.
49. Piedimonte G, Nadel JA, Long CS, Hoffman JIE. Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykininn degradation. Circ Res 1994;75:770-779.
50. Rakugi H, Duk-Kiung K, Krieger J, Wang D, Dzau V, Pratt R. Induction of angiotensin-converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 1994;93:339-346.
51. Richards AM, Crozier IG, Kosoglou T, et al. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension 1993,22:119-126.
52. Richards AM, Wittert G, Espiner EA, Yandle TG, Frampton C, Ikram H. EC 24.11 inhibition in man alters clearance of atrial natriuretic peptide. J Clin Endocrinol Metab 1991,72:1317-1322.
53. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992;71:1501-1507.
54. Roques BP, Fournie-Zaluski MC, Soroca E, et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 1980;288:286-288.
55. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993;45:87-146.
56. Schunkert H, Dzau V, Tang S, Hirsch A, Apstein C, Lorell B. Increased rat cardiac angiotensin-converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation J Clin invest 1990,86:1913-1920.
57. Seymour AA, Asaad MM, Abboa-Offei BE, Rovnyak P, Fennell S, Rogers L. Potentiation of brain natriuretic peptide by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats. J Pharmacol Exp Ther 1992;262 60-70.
58. Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL. Systemic hemodynamics, renal function, and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993,266:872-883.
59. Seymour AA, Swerdel J, Obboa-Offei B Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1991;17.456-465.
60. Showalter CJ, Zimmerman RS, Schwab TR, Edwards BS, Opgenorth TJ, Burnett JJ. Renal response to atrial natriuretic factor is modulated by intrarenal angiotensin II. Am J Physiol 1988,254:R453-456.
61. Skidgel RA, Schultz WW, Tam LT, Erdos EG Human renal angiotensin I-converting enzyme and neutral endopeptidase. Kidney Int 1987;31.45-48.
62. Smallridge RC, Gamblin GT, Eil C. Angiotensin-converting enzyme: Characteristics in human skin fibroblasts. Metabolism 1986,35:899-904.
63. Soleilhac JM, Lucas E, Beaumont A, et al. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium Mol Pharmacol 1992,41:609-614.
64. Stephenson SL, Kenny AJ Metabolism of neutropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes Biochem J 1987,241:237-247.
65. Stergiou GS, Hannah JA, Bevan EG, et al. Combined atriopeptidase inhibition and converting enzyme inhibition in hypertensive patients. J Hypertension 1994;12:1310.
66. Sugimoto T, Ishii M, Matsuoka H, et al. Increased release of atrial natriuretic polypeptides in rats with DOCA-salt hypertension. Life Sci 1986;38:1351-1358.
67. Sweet CS, Gross DM, Arbegast PT, et al. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther 1981;216:558-566.
68. Sybertz EJ, Chiu PJ, Vamulapalli S, Watkins R, Haslanger MF. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826: An orally active neutral metalloendopeptidase inhibitor. Hypertension 1990,15:152-161.
69. Trapani AJ, Smits GJ, McGraw DE, et al Thiorphan, an inhibitor of endopetidase 24 11, potentiates the natriuretic activity of atrial natriuretic peptide. J Cardiovasc Pharmacol 1989;14:419-424.
70. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Asaad MM Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267 108-116
71. Trippodo NC, Robl JA, Asaad MM, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure J Pharmacol Exp Ther 1995;275:745-752
72. Turcaud S, Gonzalez W, Michel JB., Roques BP, Fournié-Zaluski MC. Diasteroselective synthesis of mixanpril, an orally active dual inhibitor of neutral endopeptidase and angiotensin converting enzyme. Bioorg Med Chem Lett 1995;5:1893-1898
73. Ura N, Carretero OA, Erdos EG Role of renal endopeptidase 24 11 in kinin metabolism in vitro and in vivo. Kidney Int 1987;32:507-513.
74. Webb RL, Yasay GD, MacMartin C, McNeal RB, Zimmerman MB. Degradation of atrial natriuretic peptide: Pharmacologic effects of protease EC 24.11 inhibition. J Cardiovasc Pharmacol 1989;14.285-293.
75. Wilkins MR, Nunez DJ, Wharton J The natriuretic peptide family. Turning hormones into drugs J Endocrinol 1993;1;37:347-3,59.
76. Wong KR, Xie MH, Shi LB, et al. Urinary cGMP as a biological marker of the renal activity of atrial natriuretic factor. Am J Physiol 1988;255:F1220-1224.
77. Yamamoto K, Chappell MC, Brosnihan K, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 1992;19:692-696
78. Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin Biochim Biophys Acta 1970;214:374-376.